Literature DB >> 33404976

Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Tanaya R Vaidya1, Hardik Mody1, Yesenia L Franco1, Ashley Brown2, Sihem Ait-Oudhia3.   

Abstract

Dose-dependent life-threatening doxorubicin-induced cardiotoxicity (DIC) is a major clinical challenge that needs to be addressed. Here, we developed an integrated multiscale and translational quantitative systems toxicology and pharmacokinetic-toxicodynamic (QST-PK/TD) model for optimization of doxorubicin dosing regimens for early monitoring and minimization of DIC. A QST model was established by exposing human cardiomyocytes, AC16 cells, to doxorubicin over a time course, and measuring the dynamics of intracellular signaling proteins, AC16 cell viability and released biomarkers of cardiomyocyte injury such as the B-type natriuretic peptide (BNP). Experiments were scaled up to a three-dimensional and dynamic (3DD) cell culture system to evaluate DIC under various dosing regimens. The PK determinants of doxorubicin influencing DIC were identified in vitro and then translated to the in vivo setting through hybrid physiologically based PK (PBPK)/TD models using preclinical- and clinical-level data extracted from literature. The developed cellular-level QST model captured well the observed dynamics of intracellular proteins, AC16 cell viability and BNP kinetics. In the 3DD setting, dose fractionation of doxorubicin displayed a significant reduction in cardiotoxicity compared to single intravenous doses with equal exposure, implying doxorubicin peak concentrations as the PK determinant for DIC. The in vivo hybrid PBPK/TD models captured well doxorubicin PK and DIC. Peak doxorubicin concentrations correlated well with acute DIC for dose-fractionated regimens, while maximum 48-h moving average concentrations correlated with DIC for dose-fractionated and long-term infusion regimens in vivo. The developed multiscale and translational QST-PK/TD modeling platform may serve as an in silico tool for assessment of early toxicity and/or efficacy of developmental drugs in vitro.

Entities:  

Keywords:  Anthracyclines; Cardiac toxicity; Chemotherapy; Quantitative systems toxicology

Year:  2021        PMID: 33404976     DOI: 10.1208/s12248-020-00542-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  55 in total

1.  Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives.

Authors:  E Goormaghtigh; P Huart; R Brasseur; J M Ruysschaert
Journal:  Biochim Biophys Acta       Date:  1986-09-25

2.  Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin.

Authors:  O Marcillat; Y Zhang; K J Davies
Journal:  Biochem J       Date:  1989-04-01       Impact factor: 3.857

Review 3.  Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring.

Authors:  Nadine Wenningmann; Merle Knapp; Anusha Ande; Tanaya R Vaidya; Sihem Ait-Oudhia
Journal:  Mol Pharmacol       Date:  2019-06-04       Impact factor: 4.436

4.  Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.

Authors:  Brian B Hasinoff; Kareena L Schnabl; Rosemary A Marusak; Daywin Patel; Erwin Huebner
Journal:  Cardiovasc Toxicol       Date:  2003       Impact factor: 3.231

5.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

6.  Mitochondrial membrane modifications induced by adriamycin-mediated electron transport.

Authors:  E Goormaghtigh; G Pollakis; J M Ruysschaert
Journal:  Biochem Pharmacol       Date:  1983-03-01       Impact factor: 5.858

7.  Clinical evaluation of adriamycin, a new antitumour antibiotic.

Authors:  G Bonadonna; S Monfardini; M De Lena; F Fossati-Bellani
Journal:  Br Med J       Date:  1969-08-30

8.  Evidence of a covalent linkage in the adriamycin-cardiolipin complex induced by adriamycin-mediated electron transport.

Authors:  E Goormaghtigh; J M Ruysschaert
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1983-10

9.  ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes.

Authors:  Jiahao Liu; Weike Mao; Bo Ding; Chang-seng Liang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-05       Impact factor: 4.733

Review 10.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.